Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Burkitt Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 5venetoclax 3tagraxofusp 3fludarabine phosphate 3Whole-Body Irradiation 3Thiotepa 3Mycophenolic Acid 3Methotrexate 3merphos 2Tacrolimus 2Cyclosporins 2Cyclosporine 2prednylidene 1lorvotuzumab mertansine 1fludarabine 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1azathiopurine 1auricularum 1X-Rays 1Vincristine 1Specimen Handling 1Sirolimus 1Rituximab 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Blastic Plasmacytoid Dendritic Cell Neoplasm × Medrol Veriderm × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡